Abstract: The present disclosure, in some aspects, provides compositions, systems and methods for proximity-based detection of target biomolecules of interest.
Type:
Grant
Filed:
March 3, 2017
Date of Patent:
May 19, 2020
Assignee:
The Broad Institute, Inc.
Inventors:
Alon Goren, Robert Nicol, Harris Nusbaum
Abstract: Methods and systems for encoding digital information in nucleic acid (e.g., deoxyribonucleic acid) molecules without base-by-base synthesis, by encoding bit-value information in the presence or absence of unique nucleic acid sequences within a pool, comprising specifying each bit location in a bit-stream with a unique nucleic sequence and specifying the bit value at that location by the presence or absence of the corresponding unique nucleic acid sequence in the pool But, more generally, specifying unique bytes in a bytestream by unique subsets of nucleic acid sequences. Also disclosed are methods for generating unique nucleic acid sequences without base-by-base synthesis using combinatorial genomic strategies (e.g., assembly of multiple nucleic acid sequences or enzymatic-based editing of nucleic acid sequences).
Type:
Grant
Filed:
December 21, 2017
Date of Patent:
May 12, 2020
Assignee:
CATALOG TECHNOLOGIES, INC.
Inventors:
Nathaniel Roquet, Hyunjun Park, Swapnil P. Bhatia
Abstract: Compositions and methods for using nucleosome interacting protein domains to increase accessibility of programmable DNA modification proteins to target chromosomal sequences, thereby increasing efficiency of targeted genome/epigenetic modification in eukaryotic cells.
Type:
Grant
Filed:
July 10, 2018
Date of Patent:
March 31, 2020
Assignee:
Sigma-Aldrich Co. LLC
Inventors:
Fuqiang Chen, Xiao Ding, Yongmei Feng, Gregory D. Davis
Abstract: A method includes: (1) applying stimulations to a system, wherein applying the stimulations includes modulating, over time, characteristics of the stimulations; (2) measuring a time-varying response of the system to the stimulations; (3) fitting the time-varying response of the system into a model of the system; and (4) using the model of the system, identifying an optimized combination of characteristics of the stimulations to yield a desired response of the system.
Type:
Grant
Filed:
July 29, 2014
Date of Patent:
March 31, 2020
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: A protein reporter system comprising at least one reporter including a response element responsive to the binding of a transcription factor, a secreted enzyme backbone and a recognition region for specific binding of an antibody. Multiplexed assays for binding, assaying and quantifying the activity of transcription factors are also described, in which the assays use protein reporters in sets, libraries or other groupings, as necessary to achieve desired quantification.
Abstract: Methods for diagnosis of sepsis are disclosed. In particular, the invention relates to the use of biomarkers for aiding diagnosis, prognosis, and treatment of sepsis, and to a panel of biomarkers that can be used to distinguish sepsis from noninfectious sources of inflammation, such as caused by traumatic injury, surgery, autoimmune disease, thrombosis, or systemic inflammatory response syndrome (SIRS).
Type:
Grant
Filed:
March 12, 2016
Date of Patent:
January 14, 2020
Assignee:
THE BOARD OF TRUSTEE OF THE LELAND STANFORD JUNIOR UNIVERSITY
Abstract: The present invention relates to the field of analysis of the three-dimensional structure of the genome, i.e., for genome architecture mapping (GAM). The invention provides a method of determining spatial proximity of a plurality of nucleic acid loci in a compartment such as the cell nucleus, by exploiting their co-segregation amongst fractions of that compartment, identified upon separation of the nucleic acid loci from each other depending on their localization in the compartment to obtain a collection of fractions, e.g., by cryo-sectioning or cryo-milling the compartment; determining the presence or absence of the plurality of loci in the fractions; and determining the co-segregation of the plurality of loci. Co-segregation may then be analysed with statistical methods to determine spatial proximity. The method can be used e.g., for determining physical distance between a plurality of loci; and mapping loci and/or genome architecture, e.g.
Type:
Grant
Filed:
December 11, 2015
Date of Patent:
January 7, 2020
Assignees:
MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT, CAMBRIDGE ENTERPRISE LTD.
Inventors:
Ana Pombo, Paul Edwards, Mario Nicodemi, Antonio Scialdone, Robert Beagrie
Abstract: In one embodiment, a method of encoding variation data for a population comprises receiving, by a variant encoding engine executing on a processor, information describing genetic variation of a population of individuals. The information comprises a plurality of variable sites within the reference genome of the population and the genotypes of a plurality of individuals in the population with respect to those variable sites. The method further comprises selecting an encoding strategy for the information based on the characteristics of the genetic variation across the population, and encoding the information according to the selected encoding strategy. In certain embodiments, selecting an encoding strategy may comprise determining the variability of a variable site within the population, and encoding information associated with the variable site based on the variability.
Abstract: The present invention relates to a method for determining an uterine receptivity profile in order to increase implantation success in assisted fertilization.
Abstract: The present invention relates to a nucleic acid of the general formula (I): GIXmGn, which may be modified by a lipid. The invention relates further to a pharmaceutical composition containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). The present invention can relate to a vaccine, which corresponds to a pharmaceutical composition of the invention, wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention can relate to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune disease, allergies or cancer diseases.
Type:
Grant
Filed:
June 8, 2012
Date of Patent:
October 15, 2019
Assignee:
CureVac AG
Inventors:
Ingmar Hoerr, Jochen Probst, Thomas Ketterer, Birgit Scheel
Abstract: Disclosed are a method and an apparatus for detecting a translocation. The apparatus acquires BAM for a first pair of chromosomes and a second pair of chromosomes. Also, the apparatus detects a translocation generated in at least one chromosome by selecting at least one translocation case corresponding to the translocation information produced on the basis of BAM from among multiple translocation cases in which a translocation may be generated in at least one of the first and the second chromosomes.
Type:
Grant
Filed:
November 23, 2015
Date of Patent:
October 15, 2019
Assignee:
ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
Inventors:
Min-Ho Kim, Dae-Hee Kim, Ho-Youl Jung, Young-Won Kim, Myung-Eun Lim, Jae-Hun Choi, Young-Woong Han
Abstract: The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto.
Type:
Grant
Filed:
June 30, 2016
Date of Patent:
October 8, 2019
Assignee:
CureVac AG
Inventors:
Jochen Probst, Ingmar Hoerr, Thomas Lander
Abstract: The present disclosure generally relates to compositions and methods for improving the efficiency of homologous recombination. In particular, the disclosure relates to reagents and the use of such reagents.
Type:
Grant
Filed:
May 25, 2017
Date of Patent:
October 1, 2019
Assignee:
LIFE TECHNOLOGIES CORPORATION
Inventors:
Xiquan Liang, Robert Potter, Namritha Ravinder
Abstract: Methods and systems are provided for sample preparation techniques and sequencing of macromolecular constituents of cells and other biological materials.
Type:
Grant
Filed:
February 2, 2018
Date of Patent:
October 1, 2019
Assignee:
10X GENOMICS, INC.
Inventors:
Kamila Belhocine, Rajiv Bharadwaj, Christopher Hindson, Michael Schnall-Levin, Bill Lin, Anthony Makarewicz, Pranav Patel, Katherine Pfeiffer, Andrew D. Price, Mohammad Rahimi Lenji, Tobias Daniel Wheeler, Yifeng Yin
Abstract: A method of enriching for a population of RNA molecules in a mixture of RNAs is provided. In some embodiments, the method may comprise (a) adding an affinity tag to the 5? end of 5?-diphosphorylated or 5?-triphosphorylated RNA molecules in a sample by incubating the sample with an affinity tag-labeled GTP and a capping enzyme; and (b) enriching for RNA comprising the affinity tag-labeled GMP using an affinity matrix that binds to the affinity tag.
Type:
Grant
Filed:
April 25, 2016
Date of Patent:
October 1, 2019
Assignee:
New England Biolabs, Inc.
Inventors:
Ira Schildkraut, Laurence Ettwiller, Ivan R. Correa, Jr., Michael Sproviero
Abstract: The disclosure provides methods and kits for preparing sequencing library to detect chromosomal abnormality using cell-free DNA (cfDNA) without the need of first isolating the cfDNA from a liquid fraction of a test sample. In some embodiments, the method involves reducing the binding between the cfDNA and nucleosomal proteins without unwinding the cfDNA from the nucleosomal proteins. In some embodiments, the reduction of binding may be achieved by treating with a detergent or heating. In some embodiments, the method further involves freezing and thawing the test sample before reducing the binding between the cfDNA and the nucleosomal proteins. In some embodiments, the test sample is a peripheral blood sample from a pregnant woman including cfDNA of both a mother and a fetus. In other embodiments, the test sample is a peripheral blood sample from a patient known or suspected to have cancer.
Abstract: In one embodiment, the present invention relates to a method for optimizing cell-type specific protein expression. In another embodiment, the present invention relates to a method for creating a tRNA profile of a cell.
Abstract: The current invention reports a promoter that has the nucleic acid sequence of SEQ ID NO: 02 or SEQ ID NO: 03 which is a human CMV major immediate-early (hCMV-MIE) promoter/enhancer with C to G point mutation at position ?41 and/or ?179 relative to the transcription start site. This new promoter is especially useful for the production of polypeptides at large scale as it shows reduced promoter silencing and improved polypeptide production.